Accounts in Drug Discovery

Case Studies in Medicinal Chemistry
Herausgeber: Barrish, Joel; Zahler, Robert; Cheng, Peter; Carter, Percy

• Gebundenes Buch

Produktbeschreibung

Accounts in Drug Discovery describes recent case studies in medicinal chemistry with a particular emphasis on how the inevitable problems that arise during any project can be surmounted or overcome.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Drug Discovery
• Verlag: Royal Society of Chemistry
• Seitenzahl: 370
• Erscheinungstermin: 30. September 2010
• Englisch
• Abmessung: 242mm x 164mm x 27mm
• Gewicht: 712g
• ISBN-13: 9781849731263
• ISBN-10: 1849731268
• Artikelnr.: 31192958

Autorenporträt

Joel C. Barrish was awarded his Ph.D. in Organic Chemistry from Columbia University; spent 25 years as a medicinal chemist in Drug Discovery Research; co-inventor of the anti-cancer agent SPRYCEL and is currently Vice President in Discovery Chemistry responsible for multiple programs across therapeutic areas. Percy H. Carter was awarded his Ph.D. in Organic Chemistry from Harvard University; 10 years as a medicinal chemist in Drug Discovery Research and is currently Group Director in Discovery Chemistry responsible for multiple programs Inflammation Research. Peter T. W. Cheng was awarded Ph.D. in Organic Chemistry from the University of Toronto; approximately 20 yrs as a medicinal chemist in Drug Discovery Research and is currently a Research Fellow in Metabolic Diseases Chemistry. Robert Zahler gained his Ph.D. in Organic Chemistry from the California Institute of Technology; approximately 30 yrs experience as a medicinal chemist in Drug Discovery Research and is the inventor of the anti-infective agent Entecavir.

Inhaltsangabe

Front Matter; Foreword; Preface; Contents; Chapter 1. The Discovery of the
Dipeptidyl Peptidase-4 (DPP4) Inhibitor OnglyzaÖ: From Concept to Market;
Chapter 2. The Discovery of Vorapaxar (SCH 530348), a Thrombin Receptor
(Protease Activated Receptor-1) Antagonist with Potent Antiplatelet
Effects; Chapter 3. The Discovery of Piragliatin, a Glucokinase Activator;
Chapter 4. The Discovery of OSI-906, a Small-molecule Inhibitor of the
Insulin-like Growth Factor-1 and Insulin Receptors; Chapter 5. The Genesis
of the Antibody Conjugate Gemtuzumab Ozogamicin (Mylotarg«) for Acute
Myeloid Leukemia; Chapter 6. Novel Androgen Receptor Antagonists for the
Treatment of Prostate Cancer; Chapter 7. The Discovery of UK-390957: the
Challenge of Targeting a Short Half-life, Rapid Tmax SSRI; Chapter 8. The
Discovery of the Long-acting PDE5 Inhibitor PF-489791 for the Treatment of
Pulmonary Hypertension; Chapter 9. From HTS to Market: the Discovery and
Development of Maraviroc, a CCR5 Antagonist for the Treatment of HIV;
Chapter 10. The Discovery of GS-9131, an Amidate Prodrug of a Novel
Nucleoside Phosphonate HIV Reverse Transcriptase Inhibitor; Chapter 11.
2'-F-2'-C-Methyl Nucleosides and Nucleotides for the Treatment of Hepatitis
C Virus: from Discovery to the Clinic; Chapter 12. A Case History on the
Challenges of Central Nervous System and Dual Pharmacology Drug Discovery;
Chapter 13. The Discovery of TRPV1 Antagonists: Turning up the Heat;
Chapter 14. Uncoupling Neuroprotection from Immunosuppression: the
Discovery of ILS-920; Chapter 15. Identification of a7 Nicotinic
Acetylcholine Receptor Agonists for their Assessment in Improving Cognition
in Schizophrenia; Subject Index